CME Webcast featuring Dr. Poon on Recent Advances in Management of Hepatocellular Carcinoma
Investors' corner
Founded in 1982, with a vision of using heat to kill cancer and treat other diseases, Celsion began trading publicly in 1985 under the name Cheung Laboratories, Inc. The early research focus of the company was device-oriented heat-based treatment systems. In the mid-1990s, Celsion focused its efforts on expanding the Company's research portfolio and licensed a technology for the treatment of Benign Prostatic Hyperplasia (BPH), and a heat activated liposomal drug delivery system. The company was renamed Celsion Corporation and listed on the American Stock Exchange under the symbol CLN, in 2000. In 2001, Celsion determined that its heat-activated liposomal drug delivery system presented the greatest potential for creation of long-term shareholder value and redirected its strategy to transition out of device development in order to focus exclusively on drug development.
Since 2001, Celsion has completed the development of the BPH technology, obtained FDA approval to market the device and commercialized it as the Prolieve Thermodilatation® system. In June 2007, Boston Scientific Corporation acquired the Prolieve Thermodilatation system assets for $60 million. With this sale, Celsion completed its transition and became a fully focused drug development company. The company has developed its first drug, ThermoDox® , an encapsulation of doxorubicin, a frequently used, well-known, cancer drug, in the heat-activated liposome. A Phase I clinical study for the treatment of recurrent breast cancer at the chest wall is currently under way as is a Phase III clinical study for the treatment of primary liver cancer before the end of 2007, using ThermoDox in combination with 'heat' energy and radiofrequency ablation, respectively, as agents to trigger the drug delivery (release).
Recent releases
Jan 25, 2010
Celsion to Host Research and Development Day in New York City on February 24, 2010
Jan 21, 2010
Celsion Abstract Selected for Oral Presentation at 2010 IHPBA World Congress in Buenos Aires, Argentina
Jan 8, 2010
Celsion Announces CFO Departure
Dec 14, 2009
Celsion Announces Treatment of First Patient in China in Global Phase III ThermoDox(R) Trial for Primary Liver Cancer
Events & presentations
Nov 10, 2009 at 11:00 AM ET
Celsion Corporation Q3 2009 Earnings Call
View all events & presentations »